Nucala's generic name is mepolizumab. [1]
What is mepolizumab (Nucala) used to treat?
Mepolizumab is a medication used to treat severe eosinophilic asthma. It is also indicated for other conditions characterized by high levels of eosinophils, such as eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES). [2]
How does mepolizumab work?
Mepolizumab targets interleukin-5 (IL-5), a protein that plays a key role in the growth, activation, and survival of eosinophils. By blocking IL-5, mepolizumab reduces the number of eosinophils in the body, which helps to alleviate symptoms in conditions where eosinophils are implicated. [3]
When does the patent for Nucala expire?
Information regarding specific patent expiry dates for Nucala can be found on DrugPatentWatch.com. [4] Patent expirations are crucial for understanding when generic versions of a drug may become available.
Can a generic version of Nucala be developed?
The development of a generic version of mepolizumab, a biologic drug, is complex. Biologics are manufactured from living organisms, and replicating them exactly for generic (biosimilar) versions can be challenging. Regulatory bodies have specific pathways for approving biosimilars that demonstrate no clinically meaningful differences compared to the reference biologic. [5]
Who makes Nucala?
Nucala is manufactured by GlaxoSmithKline (GSK). [1]
What are the side effects of mepolizumab?
Common side effects associated with mepolizumab treatment include headache, injection site reactions, and back pain. Less common but more serious side effects can include allergic reactions. [2]
What are the alternatives to Nucala for severe asthma?
Other treatment options for severe asthma may include other biologics that target different inflammatory pathways, oral corticosteroids, and long-acting bronchodilators. The choice of treatment depends on the specific characteristics of the patient's asthma, including the underlying inflammatory profile. [6]
How is mepolizumab administered?
Mepolizumab is typically administered as an injection under the skin by a healthcare professional. [2]
What clinical trials have been conducted for mepolizumab?
Numerous clinical trials have evaluated the efficacy and safety of mepolizumab in various patient populations, including those with severe eosinophilic asthma, EGPA, and HES. These trials have assessed its impact on disease exacerbations, lung function, and quality of life. [7]
---
Sources:
[1] https://www.drugs.com/nucala.html
[2] https://www.rxlist.com/nucala-drug.htm
[3] https://www.drugbank.ca/drugs/DB09306
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/news-events/public-health-focus/biosimilars
[6] https://www.ginasthma.org/
[7] https://clinicaltrials.gov/ct2/results?cond=&term=mepolizumab